Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update News provided by Share this article Share this article MARLBOROUGH, Mass., May 13, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended March 31, 2021 and provided a business update. "This year has started out with great momentum across our pipeline, as we continue...